Paula A. Johnson - 23 Aug 2023 Form 5 Insider Report for JOHNSON & JOHNSON (JNJ)

Reporting relationship: Director
Issuer ticker: JNJ
Reported as of: 23 Aug 2023
Net transaction value: $0
SEC form: 5
Accepted by SEC: 28 Jan 2026, 18:29:28 UTC
Prior SEC filing: 02 May 2023
Next SEC filing: 29 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Joleen Morgan, as attorney-in-fact for Paula A. Johnson

Key filing fact

Paula A. Johnson filed Form 5 for JOHNSON & JOHNSON (JNJ) on 28 Jan 2026.

Key facts

This page summarizes Paula A. Johnson's Form 5 filing for JOHNSON & JOHNSON (JNJ).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jan 2026, 18:29.

Change

Previous filing in this sequence was filed on 02 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reporting Owners (1)

CIK 0001341161 Primary reporting owner

Johnson Paula A

Relationship: Director
Address: ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK
Signature: /s/ Joleen Morgan, as attorney-in-fact for Paula A. Johnson
Signature date: 28 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JNJ transaction

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -11
Change %: -11%
Price: $0.000000
Shares after: 89
Date: 23 Aug 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.